{"?xml":{"@version":"1.0"},"edm:RDF":{"@xmlns:dc":"http://purl.org/dc/elements/1.1/","@xmlns:edm":"http://www.europeana.eu/schemas/edm/","@xmlns:wgs84_pos":"http://www.w3.org/2003/01/geo/wgs84_pos","@xmlns:foaf":"http://xmlns.com/foaf/0.1/","@xmlns:rdaGr2":"http://rdvocab.info/ElementsGr2","@xmlns:oai":"http://www.openarchives.org/OAI/2.0/","@xmlns:owl":"http://www.w3.org/2002/07/owl#","@xmlns:rdf":"http://www.w3.org/1999/02/22-rdf-syntax-ns#","@xmlns:ore":"http://www.openarchives.org/ore/terms/","@xmlns:skos":"http://www.w3.org/2004/02/skos/core#","@xmlns:dcterms":"http://purl.org/dc/terms/","edm:WebResource":[{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-COJDO0X7/311d5e2a-8e9c-4bdd-ba09-fb2f51f13ec5/PDF","dcterms:extent":"1408 KB"},{"@rdf:about":"http://www.dlib.si/stream/URN:NBN:SI:DOC-COJDO0X7/d98278bb-cd4d-4b42-b10a-884e1461eac4/TEXT","dcterms:extent":"26 KB"}],"edm:TimeSpan":{"@rdf:about":"2022-2025","edm:begin":{"@xml:lang":"en","#text":"2022"},"edm:end":{"@xml:lang":"en","#text":"2025"}},"edm:ProvidedCHO":{"@rdf:about":"URN:NBN:SI:DOC-COJDO0X7","dcterms:isPartOf":[{"@rdf:resource":"https://www.dlib.si/details/URN:NBN:SI:spr-UCB4A42Q"},{"@xml:lang":"sl","#text":"Placebo"}],"dcterms:issued":"2025","dc:creator":"Planinšek, Pia","dc:format":[{"@xml:lang":"sl","#text":"številka:4"},{"@xml:lang":"sl","#text":"str. 41-45"}],"dc:identifier":["COBISSID_HOST:248505347","ISSN:2820-5014","URN:URN:NBN:SI:doc-COJDO0X7"],"dc:language":"sl","dc:publisher":{"@xml:lang":"sl","#text":"Fakulteta za farmacijo, ŠSSFD"},"dc:subject":[{"@xml:lang":"sl","#text":"celična imunoterapija"},{"@xml:lang":"en","#text":"cellular immunotherapy"},{"@xml:lang":"en","#text":"FDA approval"},{"@xml:lang":"sl","#text":"Imunoterapija"},{"@xml:lang":"sl","#text":"lifileucel"},{"@xml:lang":"sl","#text":"limfociti"},{"@xml:lang":"en","#text":"lymphocytes"},{"@xml:lang":"sl","#text":"Melanom"},{"@xml:lang":"en","#text":"melanoma"},{"@xml:lang":"sl","#text":"odobritev FDA"},{"@xml:lang":"sl","#text":"terapija s TIL"},{"@xml:lang":"en","#text":"TIL therapy"}],"dcterms:temporal":{"@rdf:resource":"2022-2025"},"dc:title":{"@xml:lang":"sl","#text":"Lifileucel – prva celična terapija za zdravljenje melanomov| splošno o dermatoveneroloških boleznih|"},"dc:description":[{"@xml:lang":"sl","#text":"Melanoma is an aggressive form of skin cancer. Its incidence is increasing worldwide, and as advanced melanomas are often resistant to standard therapies, there is a growing need for new therapeutic approaches. One such approach is lifi leucel, the fi rst approved cell therapy with tumorinfi ltrating lymphocytes (TILs) for the treatment of unresectable or metastatic melanoma. Lifi leucel uses the patient's own T lymphocytes, which are isolated from the tumor, to specifi cally target the tumor tissue. In clinical studies, the therapy has proven eff ective in patients for whom conventional immunotherapies have failed. Approval by the U.S. Food and Drug Administration (FDA) in February 2024 is an important milestone in the treatment of solid tumors"},{"@xml:lang":"sl","#text":"Melanom je agresivna oblika kožnega raka. Njegova incidenca globalno narašča. Napredovalna oblika melanoma je pogosto odporna proti standardnim terapijam, zato se pojavlja potreba po novih terapevtskih pristopih. Eden takšnih je lifi leucel, ki je prva odobrena celična terapija z limfociti, ki infi ltrirajo tumor (angl. tumor-infi ltrating lymphocytes, TIL) za zdravljenje neresektabilnega ali metastatskega melanoma. V terapiji z lifi leucelom uporabimo bolnikove lastne limfocite T, izolirane iz tumorja, za usmerjeno delovanje na tumorsko tkivo. V kliničnih študijah se je terapija izkazala za učinkovito pri bolnikih, pri katerih običajne imunoterapije niso bile uspešne. Odobritev s strani ameriške vladne uprave za zdravila in prehrano (angl. Food and Drugs Administration, FDA) februarja 2024 predstavlja pomemben mejnik v zdravljenju trdnih tumorjev"}],"edm:type":"TEXT","dc:type":[{"@xml:lang":"sl","#text":"znanstveno časopisje"},{"@xml:lang":"en","#text":"journals"},{"@rdf:resource":"http://www.wikidata.org/entity/Q361785"}]},"ore:Aggregation":{"@rdf:about":"http://www.dlib.si/?URN=URN:NBN:SI:DOC-COJDO0X7","edm:aggregatedCHO":{"@rdf:resource":"URN:NBN:SI:DOC-COJDO0X7"},"edm:isShownBy":{"@rdf:resource":"http://www.dlib.si/stream/URN:NBN:SI:DOC-COJDO0X7/311d5e2a-8e9c-4bdd-ba09-fb2f51f13ec5/PDF"},"edm:rights":{"@rdf:resource":"http://rightsstatements.org/vocab/InC/1.0/"},"edm:provider":"Slovenian National E-content Aggregator","edm:dataProvider":{"@xml:lang":"en","#text":"National and University Library of Slovenia"},"edm:object":{"@rdf:resource":"http://www.dlib.si/streamdb/URN:NBN:SI:DOC-COJDO0X7/maxi/edm"},"edm:isShownAt":{"@rdf:resource":"http://www.dlib.si/details/URN:NBN:SI:DOC-COJDO0X7"}}}}